Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H9T4 | ISIN: SE0010546242 | Ticker-Symbol: 2LU
München
21.01.25
08:00 Uhr
0,420 Euro
0,000
0,00 %
Branche
Elektrotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACCONEER AB Chart 1 Jahr
5-Tage-Chart
ACCONEER AB 5-Tage-Chart
GlobeNewswire (Europe)
158 Leser
Artikel bewerten:
(0)

Acconeer AB: Bulletin from the Extraordinary General Meeting in Acconeer AB

Finanznachrichten News

Acconeer AB (the "Company") has today, 1 March 2024, held an Extraordinary General Meeting (the "EGM"). The EGM resolved approve the Board of Directors' proposal to amend the Articles of Association and to resolve on an issue authorization for the Board of Directors. Notice of the Extraordinary General Meeting and complete proposals are available on the Company's website, www.acconeer.com.

Amendment of the Articles of Association

The EGM resolved in accordance with the Board of Directors' two proposals to amend §§ 4-5 of the Articles of Association, entailing:

  • that the Articles of Association shall be amended so that the share capital shall be not less than SEK 1,250,000 and not more than SEK 5,000,000 and that the number of shares shall be not less than 25,000,000 and not more than 100,000,000, and
  • that the Articles of Association shall be amended so that the share capital shall be not less than SEK 5,000,000 and not more than SEK 20,000,000 and that the number of shares shall be not less than 100,000,000 and not more than 400,000,000.

The EGM further resolved to authorize the Board of Directors to register with the Swedish Companies Registration Office the above resolution to amend the Articles of Association, the limits of which for the minimum and maximum number of shares in the Company are consistent with the total number of shares in the Company after the Board of Directors has resolved on a new issue of shares based on the issue authorization as set out below.

Issue authorization

The EGM resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors to, on one or more occasions during the period until the next Annual General Meeting, resolve to issue new shares, warrants and/or convertibles, with preferential rights for the Company's shareholders. The Company's share capital and the number of shares may, by virtue of the authorization, be increased with an amount and number that falls within the limits of the, at any time registered, or by the EGM adopted, Articles of Association. In accordance with what has been previously communicated, the Board of Directors intends to resolve on a rights issue of shares of approximately SEK 150 million based on the issue authorization around 5 March 2024.

For additional information, please contact:
Lars Lindell, CEO Acconeer, Phone: +46 10218 92 00, E-mail: ir@acconeer.com

About Acconeer AB
With ground-breaking technology, Acconeer has developed a radar sensor that opens a new world of interaction. Acconeer Micro Radar Sensor, with low power consumption, high precision, small size and high robustness, is a 60GHz robust and cost-effective sensor for detection, distance measurement, motion detection and camera-supported applications with low power consumption. Acconeer combines the advantage of low power consumption with highly accurate pulsed radar systems of coherent radar, all integrated into a component with a surface area of only 28 mm2. The radar sensor can be included in a range of mobile consumer products, from smartphones to wearables, but also in areas such as robots, drones, the Internet of Things, healthcare, automotive, industrial robots and security and monitoring systems. Acconeer is a semiconductor company and, as a business model, sells hardware to manufacturers of consumer electronics products. Acconeer is listed on Nasdaq First North Growth Market with the ticker code ACCON, Redeye is the company's Certified Advisor (CA). For more information: www.acconeer.com.

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.